The prevalence of co-prescription of clinically relevant CYP enzyme inhibitor and substrate drugs in community-dwelling elderly Australians

Journal of Clinical Pharmacy and Therapeutics

Volumn 39, Issue 4, 2014, Pages 383-389

  Kerr, K P ^a   Mate, K E ^a   Magin, P J ^b   Marley, J ^c   Stocks, N P ^d   Disler, P ^e   Pond, C D ^b  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d UNIVERSITY OF ADELAIDE   (Australia)

^e MONASH UNIVERSITY   (Australia)

Author keywords

CYP 2D6; CYP3A4; cytochrome P450; drug drug interactions; elderly; polypharmacy

Indexed keywords

AMIODARONE; AMITRIPTYLINE; ATORVASTATIN; CIPROFLOXACIN; CLARITHROMYCIN; CODEINE; CYTOCHROME P450 2D6; CYTOCHROME P450 INHIBITOR; DILTIAZEM; DOXEPIN; FLECAINIDE; FLUOXETINE; FLUVOXAMINE; METOPROLOL; MOCLOBEMIDE; OMEPRAZOLE; PAROXETINE; PERHEXILINE; QUININE; RABEPRAZOLE; RISPERIDONE; SERTRALINE; SIMVASTATIN; TERBINAFINE; TICLOPIDINE; UNINDEXED DRUG; VENLAFAXINE; VERAPAMIL; VORICONAZOLE; WARFARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGED; AREA UNDER THE CURVE; ARTICLE; AUSTRALIA; CLINICAL ASSESSMENT; COMMUNITY LIVING; DEPRESSION; DRUG PROTEIN BINDING; ENZYME SUBSTRATE; FEMALE; GENERAL PRACTITIONER; GERIATRIC PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL FUNCTION; PRESCRIPTION; PREVALENCE; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; RISK BENEFIT ANALYSIS; CLINICAL PRACTICE; CLINICAL TRIAL; COGNITION DISORDERS; DRUG INTERACTION; MULTICENTER STUDY; POLYPHARMACY; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AUSTRALIA; COGNITION DISORDERS; CYTOCHROME P-450 ENZYME INHIBITORS; DEPRESSION; DRUG INTERACTIONS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PHYSICIAN'S PRACTICE PATTERNS; POLYPHARMACY; PREVALENCE; QUALITY OF LIFE;

EID: 84904211065     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/jcpt.12163     Document Type: Article

References (39)

1. Lazarou J, Pomeranz BH, Corey PN,. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA, 1998; 279: 1200-1205.
2. Wester K, Jonsson AK, Spigset O, Druid H, Hagg S,. Incidence of fatal adverse drug reactions: a population based study. Br J Clin Pharmacol, 2008; 65: 573-579.
3. Yoshida M, Matsumoto T, Suzuki T, Kitamura S, Mayama T,. Effect of concomitant treatment with a CYP3A4 inhibitor and a calcium channel blocker. Pharmacoepidemiol Drug Saf, 2008; 17: 70-75.
4. Williams JA, Hyland R, Jones BC, et al,. Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos, 2004; 32: 1201-1208.
5. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP,. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther, 1994; 270: 414-423.
6. Kolars JC, Lown KS, Schmiedlin-Ren P, et al,. CYP3A gene expression in human gut epithelium. Pharmacogenetics, 1994; 4: 247-259.
7. Dresser GK, Spence JD, Bailey DG,. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet, 2000; 38: 41-57.
8. Ingelman-Sundberg M,. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J, 2005; 5: 6-13.
9. Zhou SF,. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab, 2008; 9: 310-322.
10. Hilmer SN, McLachlan AJ, Le Couteur DG,. Clinical pharmacology in the geriatric patient. Fundam Clin Pharmacol, 2007; 21: 217-230.
11. Cadieux RJ,. Drug interactions in the elderly. How multiple drug use increases risk exponentially. Postgrad Med, 1989; 86: 179-186.
12. Milde AS, Motsch J,. Drug interactions and the anesthesiologist. Anaesthesist, 2003; 52: 839-859.
13. Mannesse CK, Derkx FH, de Ridder MA, Man in 't Veld AJ, van der Cammen TJ, Contribution of adverse drug reactions to hospital admission of older patients. Age Ageing, 2000; 29: 35-39.
14. Chen YF, Avery AJ, Neil KE, Johnson C, Dewey ME, Stockley IH,. Incidence and possible causes of prescribing potentially hazardous/contraindicated drug combinations in general practice. Drug Saf, 2005; 28: 67-80.
15. Egger SS, Ratz Bravo AE, Hess L, Schlienger RG, Krahenbuhl S,. Age-related differences in the prevalence of potential drug-drug interactions in ambulatory dyslipidaemic patients treated with statins. Drugs Aging, 2007; 24: 429-440.
16. Pergolizzi JV Jr, Labhsetwar SA, Puenpatom RA, Joo S, Ben-Joseph RH, Summers KH,. Prevalence of exposure to potential CYP450 pharmacokinetic drug-drug interactions among patients with chronic low back pain taking opioids. Pain Pract, 2011; 11: 230-239.
17. Roughead EE, Kalisch LM, Barratt JD, Gilbert AL,. Prevalence of potentially hazardous drug interactions amongst Australian veterans. Br J Clin Pharmacol, 2010; 70: 252-257.
18. Pond CD, Brodaty H, Stocks NP, et al,. Ageing in general practice (AGP) trial: a cluster randomised trial to examine the effectiveness of peer education on GP diagnostic assessment and management of dementia. BMC Fam Pract, 2012; 13: 12.
19. Sheikh JI, Yesavage JA,. Geriatric Depression Scale (GDS): Recent evidence and development of a shorter version. In:, Brink TL, ed. Clinical Gerontology: a Guide to Assessment. New York: Haworth Press, 165-173, 1986.
20. Roth M, Huppert FA, Mountjoy CQ, Tym E,. CAMDEX-R: The Cambridge examination for mental disorders of the elderly -revised. Cambridge: Cambridge University Press, 1998.
21. Hawthorne G, Herrman H, Murphy B,. Interpreting the WHOQOL-Bref: preliminary population norms and effect sizes. Soc Indic Res, 2006; 77: 37-59.
22. Flockhart D,. Drug Interactions: Cytochrome P450 Drug Interaction Table: Indiana University School of Medicine, 2007. Available at: http://medicine. iupui.edu/clinpharm/ddis/table.asp (accessed 9 December 2013).
23. Polasek TM, Lin FP, Miners JO, Doogue MP,. Perpetrators of pharmacokinetic drug-drug interactions arising from altered cytochrome P450 activity: a criteria-based assessment. Br J Clin Pharmacol, 2011; 71: 727-736.
24. Australian Medicines Handbook. Adelaide: Australian Medicines Handbook Pty Ltd, 2013.
25. United States Food and Drug Administration. Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Silver Spring, MD: US Food and Drug Administration, 2011. Available at: http://www.fda.gov/drugs/ developmentapprovalprocess/developmentresources/druginteractionslabeling/ ucm093664.htm (accessed 9 December 2013).
26. Doan J, Zakrzewski-Jakubiak H, Roy J, Turgeon J, Tannenbaum C,. Prevalence and risk of potential cytochrome P450-mediated drug-drug interactions in older hospitalized patients with polypharmacy. Ann Pharmacother, 2013; 47: 324-332.
27. Ratz Bravo AE, Tchambaz L, Krahenbuhl-Melcher A, Hess L, Schlienger RG, Krahenbuhl S,. Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy. Drug Saf, 2005; 28: 263-275.
28. Sica DA, Gehr TW,. Rhabdomyolysis and statin therapy: relevance to the elderly. Am J Geriatr Cardiol, 2002; 11: 48-55.
29. Bolego C, Baetta R, Bellosta S, Corsini A, Paoletti R,. Safety considerations for statins. Curr Opin Lipidol, 2002; 13: 637-644.
30. Law M, Rudnicka AR,. Statin safety: a systematic review. Am J Cardiol, 2006; 97: 52C-60C.
31. Bakhai A, Rigney U, Hollis S, Emmas C,. Co-administration of statins with cytochrome P450 3A4 inhibitors in a UK primary care population. Pharmacoepidemiol Drug Saf, 2012; 21: 485-493.
32. Ming EE, Davidson MH, Gandhi SK, et al,. Concomitant use of statins and CYP3A4 inhibitors in administrative claims and electronic medical records databases. J Clin Lipidol, 2008; 2: 453-463.
33. Heerey A, Barry M, Ryan M, Kelly A,. The potential for drug interactions with statin therapy in Ireland. Ir J Med Sci, 2000; 169: 176-179.
34. Law MR, Wald NJ, Rudnicka AR,. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ, 2003; 326: 1423-1427.
35. Molden E, Spigset O,. Interactions between metoprolol and antidepressants. Tidsskr Nor Laegeforen, 2011; 131: 1777-1779.
36. Desmeules J, Gascon MP, Dayer P, Magistris M,. Impact of environmental and genetic factors on codeine analgesia. Eur J Clin Pharmacol, 1991; 41: 23-26.
37. Micromedex Health Series. Drugdex System. Greenwood Village, CO: Truven Health Analytics, 2013.
38. Molden E, Garcia BH, Braathen P, Eggen AE,. Co-prescription of cytochrome P450 2D6/3A4 inhibitor-substrate pairs in clinical practice. A retrospective analysis of data from Norwegian primary pharmacies. Eur J Clin Pharmacol, 2005; 61: 119-125.
39. Zakrzewski-Jakubiak H, Doan J, Lamoureux P, Singh D, Turgeon J, Tannenbaum C,. Detection and prevention of drug-drug interactions in the hospitalized elderly: utility of new cytochrome p450-based software. Am J Geriatr Pharmacother, 2011; 9: 461-470.